Menu
Back to Journals » International Journal of Nanomedicine » Volume 3 » Issue 3
Nanocrystal technology, drug delivery and clinical applications
Authors Junghanns J, Müller R
Published 12 September 2008 Volume 2008:3(3) Pages 295—309
Jens-Uwe A H Junghanns, Rainer H Müller
Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University of Berlin, Berlin, Germany
Abstract: Nanotechnology will affect our lives tremendously over the next decade in very different fields, including medicine and pharmacy. Transfer of materials into the nanodimension changes their physical properties which were used in pharmaceutics to develop a new innovative formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do not belong to the future; the first products are already on the market. The industrially relevant production technologies, pearl milling and high pressure homogenization, are reviewed. The physics behind the drug nanocrystals and changes of their physical properties are discussed. The marketed products are presented and the special physical effects of nanocrystals explained which are utilized in each market product. Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.
Keywords: drug nanocrystals, pearl milling, high pressure homogenization, nanocrystal, DissoCubes, Nanopure, bioavailability enhancement, saturation solubility, dissolution velocity
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.